TY - JOUR

T1 - NeuroPharm study

T2 - EEG wakefulness regulation as a biomarker in MDD

AU - Ip, Cheng Teng

AU - Ganz, Melanie

AU - Dam, Vibeke H.

AU - Ozenne, Brice

AU - Rüesch, Annia

AU - Köhler-Forsberg, Kristin

AU - Jørgensen, Martin B.

AU - Frokjaer, Vibe G.

AU - Søgaard, Birgitte

AU - Christensen, Søren R.

AU - Knudsen, Gitte M.

AU - Olbrich, Sebastian

N1 - Funding Information: Collection of the data included in the study was supported by Innovationsfonden, Denmark (4108-00004B) and by the Lundbeck Foundation (Cimbi: R90-A7722). C.I. was supported by the Innovationsfonden, Denmark (5189-00087A). M.G. was supported by the Lundbeck Foundation (R181-2014-3586) and the Elsass foundation (18-3-0147). V.D. was supported by Augustinus Foundation (16-0058) and Rigshospitalet's Research (R149-A6325). M.J. was supported by Savv?rksejer Jeppe Juhl og hustru Ovita Juhls Mindelegat. V.F. was supported by Augustinus Foundation (16-0058). G.K. was supported by Innovationsfonden, Denmark (4108-00004B) Funding Information: Collection of the data included in the study was supported by Innovationsfonden , Denmark ( 4108-00004B ) and by the Lundbeck Foundation (Cimbi: R90-A7722 ). C.I. was supported by the Innovationsfonden , Denmark ( 5189-00087A ). M.G. was supported by the Lundbeck Foundation ( R181-2014-3586 ) and the Elsass foundation ( 18-3-0147 ). V.D. was supported by Augustinus Foundation ( 16-0058 ) and Rigshospitalet’s Research ( R149-A6325 ). M.J. was supported by Savværksejer Jeppe Juhl og hustru Ovita Juhls Mindelegat . V.F. was supported by Augustinus Foundation ( 16-0058 ). G.K. was supported by Innovationsfonden , Denmark ( 4108-00004B ) Publisher Copyright: © 2021 The Authors

PY - 2021

Y1 - 2021

N2 - While several electroencephalogram (EEG)-based biomarkers have been proposed as diagnostic or predictive tools in major depressive disorder (MDD), there is a clear lack of replication studies in this field. Markers that link clinical features such as disturbed wakefulness regulation in MDD with neurophysiological patterns are particularly promising candidates for e.g., EEG-informed choices of antidepressive treatment. We investigate if we in an independent MDD sample can replicate abnormal findings of EEG-vigilance regulation during rest and as a predictor for antidepressive treatment response. EEG-resting state was recorded in 91 patients and 35 healthy controls from the NeuroPharm trial. EEG-vigilance was assessed using the Vigilance Algorithm Leipzig (VIGALL). We compared the vigilance regulation during rest between patients and healthy controls and between remitters/responders and non-remitters/non-responders after eight weeks of SSRI/SNRI treatment using two different sets of response criteria (NeuroPharm and iSPOT-D). We replicated previous findings showing hyperstable EEG-wakefulness regulation in patients in comparison to healthy subjects. Responders defined by the iSPOT-D criteria showed a higher propensity toward low vigilance stages in comparison to patients with no response at pretreatment, however, this did not apply when using the NeuroPharm criteria. EEG-wakefulness regulation patterns normalized toward patterns of healthy controls after 8 weeks of treatment. This replication study supports the diagnostic value of EEG-vigilance regulation and its usefulness as a biomarker for the choice of treatment in MDD.

AB - While several electroencephalogram (EEG)-based biomarkers have been proposed as diagnostic or predictive tools in major depressive disorder (MDD), there is a clear lack of replication studies in this field. Markers that link clinical features such as disturbed wakefulness regulation in MDD with neurophysiological patterns are particularly promising candidates for e.g., EEG-informed choices of antidepressive treatment. We investigate if we in an independent MDD sample can replicate abnormal findings of EEG-vigilance regulation during rest and as a predictor for antidepressive treatment response. EEG-resting state was recorded in 91 patients and 35 healthy controls from the NeuroPharm trial. EEG-vigilance was assessed using the Vigilance Algorithm Leipzig (VIGALL). We compared the vigilance regulation during rest between patients and healthy controls and between remitters/responders and non-remitters/non-responders after eight weeks of SSRI/SNRI treatment using two different sets of response criteria (NeuroPharm and iSPOT-D). We replicated previous findings showing hyperstable EEG-wakefulness regulation in patients in comparison to healthy subjects. Responders defined by the iSPOT-D criteria showed a higher propensity toward low vigilance stages in comparison to patients with no response at pretreatment, however, this did not apply when using the NeuroPharm criteria. EEG-wakefulness regulation patterns normalized toward patterns of healthy controls after 8 weeks of treatment. This replication study supports the diagnostic value of EEG-vigilance regulation and its usefulness as a biomarker for the choice of treatment in MDD.

KW - Antidepressant treatment effect

KW - Biomarker

KW - EEG

KW - MDD

KW - SSRI

KW - VIGALL

U2 - 10.1016/j.jpsychires.2021.06.021

DO - 10.1016/j.jpsychires.2021.06.021

M3 - Journal article

C2 - 34175743

AN - SCOPUS:85108414197

VL - 141

SP - 57

EP - 65

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

SN - 0022-3956

ER -